• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Oral fluids as a live-animal sample for evaluating cross-reactivity and cross-protection following intranasal influenza A virus vaccination in pigs

tetano

Editor, Senior Moderator
Clin Vaccine Immunol. 2015 Aug 19. pii: CVI.00358-15. [Epub ahead of print]
[h=1]Oral fluids as a live-animal sample for evaluating cross-reactivity and cross-protection following intranasal influenza A virus vaccination in pigs.[/h] Hughes HR[SUP]1[/SUP], Vincent AL[SUP]1[/SUP], Brockmeier SL[SUP]1[/SUP], Gauger PC[SUP]2[/SUP], Pena L[SUP]3[/SUP], Santos J[SUP]3[/SUP], Braucher DR[SUP]1[/SUP], Perez DR[SUP]3[/SUP], Loving CL[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] In North American swine there are numerous antigenically distinct H1 influenza A virus (IAV) variants currently circulating, making vaccine development difficult due to the inability to formulate a vaccine that provides broad cross-protection. Experimentally, live-attenuated influenza virus (LAIV) vaccines demonstrate increased cross-protection compared to inactivated vaccines. However, there is no standardized assay to predict cross-protection following LAIV vaccination. Hemagglutination-inhibiting (HI) antibody in serum is the gold standard correlate of protection following IAV vaccination. LAIV vaccination does not induce a robust serum HI antibody titer; however, a local mucosal antibody response is elicited. Thus, a live-animal sample source that could be used to evaluate LAIV immunogenicity and cross-protection is needed. Here, we evaluated the use of oral fluids (OF) and nasal wash (NW) collected after IAV inoculation as a live-animal sample source in an ELISA to predict cross-protection in comparison to traditional serology. Both live-virus exposure and LAIV vaccination provided heterologous protection, though protection was greatest against more phylogenetically related viruses. IAV-specific IgA was detected in NW and OF samples and was cross-reactive against representative IAV from each H1 cluster. Endpoint titers of cross-reactive IgA in OF from pigs exposed to live-virus was associated with heterologous protection. While LAIV vaccination provided significant protection, LAIV immunogenicity was reduced compared to live-virus exposure. These data suggest that OF from pigs inoculated with wild-type IAV, with surface genes that match the LAIV seed strain, could be used in an ELISA to assess cross-protection and antigenic relatedness of circulating and emerging IAV in swine.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.


PMID: 26291090 [PubMed - as supplied by publisher]
 
Back
Top Bottom